arrow
K

Kevin J. Anstrom

University of North Carolina
H指数:83
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MAGGIC and PREDICT-HF Models in the VICTOR Trial: Do Traditional Risk Scores Still Work in Well-Treated Ambulatory Patients with HFrEF?

MAGGIC和PREDICT-HF模型在VICTOR试验中:传统风险评分在治疗良好的HFrEF门诊患者中是否仍然有效?

2026-09-210
PRE
Design characteristics of sequential multiple assignment randomised trials (SMARTs) for human health: a scoping review of studies between 2009 and 2024

人类健康领域序贯多重随机分配试验(SMARTs)的设计特征:2009年至2024年相关研究的范围综述

2025-12-010
OA
Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial

vericiguat在射血分数降低的慢性心力衰竭中的血压、安全性及临床疗效:VICTOR试验的启示

2025-09-011
PRE
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

维利西呱用于射血分数降低的心力衰竭患者:VICTORIA和VICTOR试验的个体参与者数据分析

2025-08-300
OAAI
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

维利西呱在慢性心力衰竭伴射血分数降低(VICTOR)患者中的应用:一项双盲、安慰剂对照、随机、III期临床试验

2025-08-300
PRE
Assessing Benefit in Heart Failure Patients with Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification

评估射血分数降低的心力衰竭患者的获益:使用新型预后风险分层对VICTORIA试验的分析

2025-08-280
OA
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR

维利西呱对HFrEF代偿期门诊患者心力衰竭恶化的影响:来自VICTOR研究的见解

JACC
IF0
2025-08-270
PREAI
Baseline characteristics of participants in the Biomarkers for Evaluating Spine Treatments clinical trial: a sequential multiple assignment randomized trial for chronic low back pain†

参与者在“评估脊柱治疗生物标志物”临床试验中的基线特征:一项针对慢性下背痛的序贯多重分配随机试验†

2025-08-010
OAAI
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

Butler, J.; Fioretti, F.; McMullan, C.J.; Anstrom, K.J.; Barash, I.; Bonaca, M.P.; Borentain, M.; Corda, S.; Teixeira, P.P.; Ezekowitz, J.A.; 等. 维利卡格特与射血分数降低的心力衰竭患者的死亡率:VICTOR试验。Eur. Heart J. 2025, ehaf655. [Google Scholar] [CrossRef]

2025-08-0116
OA
Multivitamins After Myocardial Infarction in Patients With Diabetes A Randomized Clinical Trial

糖尿病患者在心肌梗死后的多维生素补充:一项随机临床试验

2025-05-010
PRE
SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial

SARS-CoV-2 N蛋白和抗刺突蛋白血清学:对COVID-19疾病严重程度和死亡率的见解——ACTIV-1试验的二次分析

2025-04-220
OA
The design and rationale of the Biomarkers for Evaluating Spine Treatments trial: a sequential multiple assignment randomized trial

《评估脊柱治疗方法的生物标志物试验的设计与原理:一项序贯多重分配随机试验》

2025-04-090
PRE
Quality of Life Outcomes With a Risk-Based Precision Testing Strategy Versus Usual Testing in Stable Patients With Suspected Coronary Disease: Results From the PRECISE Randomized Trial

在疑似冠心病的稳定患者中,基于风险的精确测试策略与常规测试的生活质量结果: 来自精确随机试验的结果

2025-02-010
PRE
Economic Outcomes With Precision Diagnostic Testing Versus Usual Testing in Stable Chest Pain: Results From the PRECISE Randomized Trial

在稳定的胸痛中,精确诊断测试与常规测试的经济结果: 来自精确随机试验的结果

2025-02-010
PRE
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial
2024-10-300
OA